Articles from Radiant Biotherapeutics

Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, for a broad range of therapeutic areas, including cancer and infectious diseases, announced new data at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting demonstrating its lead oncology candidate, RBT-101, exhibited robust, durable and complete tumor regression while avoiding liver toxicity, in a MC38 colorectal mouse tumor model.

Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, to treat cancer, autoimmune and infectious diseases, today announced the Company will present data on its Multabody™ approach at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5-9, 2025 in National Harbor, MD.

Radiant Biotherapeutics, a biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody™) therapeutics for patients with cancer and autoimmune diseases, today announced the appointments of seasoned biotechnology executive Deborah Geraghty, Ph.D., as President and Chief Executive Officer, entrepreneur and venture investor Stefan Larson, Ph.D., as Chair of the Board of Directors, and distinguished physician-scientist Ingmar Bruns, M.D., Ph.D., as Board Member.

Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver first-in-class transformative therapies for patients facing life-changing disease, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago. The presentation describes the company’s Multabody™ platform, a novel approach to stimulating key targets in immunotherapy that have remained out of reach due to toxicity or lack of response.

Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has closed a $35 million Series A financing. The round is co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures of Canada.

Radiant Biotherapeutics, a startup biotechnology company developing a revolutionary antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has received a USD $2 million grant from the Bill & Melinda Gates Foundation to develop the next generation of HIV biologics based on Radiant’s Multabody™ platform.

Breakthrough platform creating multi-valent and multi-specific biotherapeutics with broad transformative applications